Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Molecular targets for therapy

The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

References

  1. Carew JS, Nawrocki ST. Drain the lysosome: development of the novel orally available autophagy inhibitor ROC-325. Autophagy. 2017;13:765–6.

    Article  CAS  Google Scholar 

  2. Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi RK, Davis LE, et al. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy. 2014;10:1403–14.

    Article  CAS  Google Scholar 

  3. Chude CI, Amaravadi RK. Targeting autophagy in cancer: update on clinical trials and novel inhibitors. Int J Mol Sci. 2017;18. pii: E1279.

  4. Carew JS, Espitia CM, Esquivel JA 2nd, Mahalingam D, Kelly KR, Reddy G, et al. Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. J Biol Chem. 2011;286:6602–13.

    Article  CAS  Google Scholar 

  5. Carew JS, Espitia CM, Zhao W, Han Y, Visconte V, Phillips J, et al. Disruption of autophagic degradation with ROC-325 antagonizes renal cell carcinoma pathogenesis. Clin Cancer Res. 2017;23:2869–79.

    Article  CAS  Google Scholar 

  6. Visconte V, Przychodzen B, Han Y, Nawrocki ST, Thota S, Kelly KR, et al. Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms. Leukemia. 2017;31:505–10.

    Article  CAS  Google Scholar 

  7. Ornstein MC, Mukherjee S, Sekeres MA. More is better: combination therapies for myelodysplastic syndromes. Best Pr Res Clin Haematol. 2015;28:22–31.

    Article  CAS  Google Scholar 

  8. Madanat Y, Sekeres MA. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity. Semin Hematol. 2017;54:147–53.

    Article  Google Scholar 

  9. Romano A, Giallongo C, La Cava P, Parrinello NL, Chiechi A, Vetro C, et al. Proteomic analysis reveals autophagy as pro-survival pathway elicited by long-term exposure with 5-azacitidine in high-risk myelodysplasia. Front Pharm. 2017;8:204.

    Article  Google Scholar 

  10. Robert G, Auberger P. Azacitidine resistance caused by LAMP2 deficiency: a therapeutic window for the use of autophagy inhibitors in MDS/AML patients? Autophagy. 2019;15:927–9.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This project was supported by grants from the National Cancer Institute (R01CA172443 to JSC and R01CA190789 to STN) and the University of Arizona Cancer Center Support Grant P30CA023074.

Author information

Authors and Affiliations

Authors

Contributions

STN contributed to the study design, performed experiments, analyzed and interpreted data, and wrote the paper. YH, VV, BP, and CME performed the experiments, analyzed and interpreted the data, and contributed to the paper preparation; analyzed and interpreted data and participated in the paper preparation. JP contributed to ROC-325 design and synthesis. FA, AA, HEC, KRK, MAS, and JPM consented patients to provide primary specimens in support of the study and participated in the data analysis and the paper preparation. JSC directed the study, performed the experiments, contributed to the data analysis and paper preparation. All authors approved the paper before submission.

Corresponding author

Correspondence to Jennifer S. Carew.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nawrocki, S.T., Han, Y., Visconte, V. et al. The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine. Leukemia 33, 2971–2974 (2019). https://doi.org/10.1038/s41375-019-0529-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-019-0529-2

This article is cited by

Search

Quick links